BioPorto share is markedly up as new CEO for US is hired, and management remains confident at event after strong Q1 report
BioPorto yesterday announced that a new CEO for its US business is appointed who will be responsible for the commercialization process in US of the company’s FDA approved NGAL-test, ProNephro AKI.
Following the announcement, BioPorto today released its 1. quarter report, showing high growth in its NGAL Test for research use only in the US and had management maintain their guidance for 2024. Later, CEO Peter Mørch Eriksen participated in an event with HCA Capital where the CEO presented the report and reiterated high confidence in BioPorto’s ability to successfully commercialize ProNephro AKI as salespeople from BioPorto and test-equipment maker and partner Roche will begin their marketing efforts of ProNephro AKI in the US in the coming quarters.
You can view the event here: Bioporto Q1
Disclaimer: HC Andersen Capital receives payment from BioPorto for a DigitalIR/Corporate visibility subscription agreement./ Henrik Ekman 13:45 08.05.2024
Login required
This content is only available for logged in users
BioPorto
BioPorto is a Danish in-vitro diagnostics company with headquarters in Copenhagen, Denmark. The company was founded in 2000. BioPorto has one marketed product, the NGAL test, for early diagnosis of acute kidney injury (AKI), which is commercially available in Europe, Canada, Asia, and Israel. It has received breakthrough designation from the FDA for AKI in the pediatric indication, for which it is currently conducting data analysis following the completion of enrollment of patients for its Phase 3 study which will lead to an expected application to FDA. Future plans include further FDA submission for adult indication as well as other markets.
Read more on company page